Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC).

@article{VillalonaCalero2004PhaseIS,
  title={Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC).},
  author={Miguel A. Villalona-Calero and Gregory Alan Otterson and Greg Wientjes and Ken Kobayashi and Randy Jensen and Donn C. Young and T Yeh and Saeheum Song and Michael R Grever and Jessie L-S Au},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={7108}
}
7108 Background: We described that elevated levels of acidic/basic fibroblastic growth factors in the extracellular medium of metastatic tumors result in tumor resistance to anticancer drugs and that low (10-15μM) suramin (S) concentrations (conc) produce reversal of resistance to paclitaxel in vivo (PNAS 2000; Cancer Res 2001). We also demonstrated that… CONTINUE READING